Question 1

What has C-peptide been measured to do, and in what model?

Accepted Answer

Three kinds of evidence exist, and they carry very different weight. Most of it is cell and animal work, a smaller part is short human infusion studies, and the rest is association. In cells, a 2023 review describes C-peptide binding to signalling molecules on the cell surface to play antioxidant, anti-apoptotic and inflammatory roles, or regulate cellular transcription through internalization. Anti-apoptotic means working against programmed cell death, and internalization means the peptide is taken inside the cell, where it can change which genes are read. A 2004 review says C-peptide either directly through interaction with its specific cell-surface receptor or indirectly through a related membrane entity exerts a unique effect on several intracellular processes. Activity in a dish shows a molecule can do something. It does not show that the body uses it to do that, and the gap between those two claims is the story of C-peptide research.

Question 2

What did C-peptide do to the kidneys?

Accepted Answer

The kidney is where the case was strongest, in rodents and in short human studies. A 2017 review says studies of C-peptide in animal models and in humans with type 1 diabetes all suggest a renoprotective effect, renoprotective meaning kidney-protecting. In people, the same review places that effect in short-term studies of type 1 diabetes, where giving C-peptide went with a lower filtration rate and less protein in the urine. Its authors put the stakes plainly, noting that there have been no new therapies for diabetic kidney disease in the last 20 years. Read that carefully. Hyperfiltration and protein in the urine are early markers of kidney strain, and a short study that shifts them is weaker than a long one that prevents kidney failure. The second kind of study does not appear among these sources.

Question 3

What did it do to red blood cells and small blood vessels?

Accepted Answer

The most detailed human work concerns a pump in the red cell wall, the Na+,K(+)-ATPase, which moves sodium out of a cell and potassium in. A 2004 review reports that in the red blood cells of type 2 diabetic patients, this pump's activity was strongly related to blood C-peptide levels. It adds that islet transplantation, which restores endogenous C-peptide secretion, enhances the pump's activity proportionally to the rise in C-peptide. The review links this to blood flow, arguing that the drop in pump activity in diabetes compromises microvascular blood flow by affecting microvascular regulation and by decreasing red blood cell deformability. Microvascular means the smallest vessels. A chain of associations runs from C-peptide to the pump to blood flow, and each link is real, but a chain of links is not the same as a measured clinical benefit.

Question 4

Has C-peptide been measured to do anything for nerves?

Accepted Answer

Indirectly, through the same pump, and the human part is association rather than trial. The 2004 review states that the defect in ATPase is strongly related to diabetic neuropathy, and that patients with neuropathy have lower ATPase activity than those without. Diabetic neuropathy is nerve damage from diabetes, usually felt first as numbness or pain in the feet. It adds that red blood cell ATPase activity is related to nerve conduction velocity in the peroneal and the tibial nerve of diabetic patients, two nerves of the lower leg. Conduction velocity is how fast a signal travels along a nerve, and it slows as nerves are damaged. The step from C-peptide to the nerve itself was taken in rats, where infusion raised the pump's activity inside the nerve. No human nerve outcome after C-peptide infusion appears among these sources, so this is a plausible route rather than a demonstrated benefit.

Question 5

What has only been shown in animals or cells?

Accepted Answer

Most of the mechanism, and the boundary is worth drawing precisely. In isolated pieces of rat kidney, the 2004 review reports that C-peptide raised pump activity in proportion to how much was added, both in the proximal tubules and in the medullary thick ascending limb of the kidney. Those are segments of the tiny tubes that turn filtered blood into urine. The same review is careful to say the effect is not indirect, since red cells from people with diabetes, kept in a dish with C-peptide at normal body concentrations, showed higher pump activity. And a 2004 signalling review notes that its authors worked without a purified receptor, the docking site a hormone usually binds to. A hormone without a confirmed docking site is a hormone whose job in the body is still argued over, and that is the fact to carry from the cell work.

Question 6

What has C-peptide been studied for in people?

Accepted Answer

The complications of type 1 diabetes, chiefly kidney and nerve disease, in short infusion studies. Blood sugar was never the target, because insulin does that job. The 2004 review reports that short-term C-peptide infusion to type 1 diabetic patients brought pump activity back to normal levels in their red cells. A 2023 review sums up where that led, saying replacement worked in animal models when C-peptide is deficient, but results from clinical trials have been unsatisfactory. That is the whole human arc in two sentences: a marker moved in short studies, and the longer trials did not deliver what the markers suggested. The amounts and settings behind those studies are examined on the C-peptide dosage page.

Question 7

Why did the animal benefits not carry into the trials?

Accepted Answer

The sources do not settle it, but they point to two reasons worth knowing. The first is a distinction built into the title of a 2021 editorial, Biological activity versus physiological function of proinsulin C-peptide, which separates what a molecule can do from what a body uses it for. That editorial adds that one prohormone could harbor more than one activity, and that the additional activities should be taken into account in the development of hormone-based therapies. The second reason is about who was studied, and the 2023 review says future replacement studies will need to focus on baseline levels of C-peptide. Put simply, giving C-peptide to someone who still makes a little is different from giving it to someone who makes none, and the trials may have mixed the two. That is a hypothesis drawn from the review, not a finding.

Question 8

Does keeping your own C-peptide bring benefits?

Accepted Answer

This is where the human evidence is firmest, with one large caveat. C-peptide and insulin leave the pancreas together, so a benefit linked with one is also a benefit linked with the other. The 2013 teplizumab trial found that the immune therapy kept insulin production going and cut the use of injected insulin in some patients with new type 1 diabetes. In one form of diabetes that starts with a sudden crisis, a 2023 review says some patients keep enough of their own insulin-making cells to come off insulin for a time. A 2020 review on type 2 diabetes adds that bringing blood sugar back to normal early may protect the cells that make insulin. In all three, C-peptide is the measure of a pancreas that still works, and the benefit is the pancreas still working. That is a good thing to have, but it is not the same as a benefit of C-peptide itself, and nobody in those studies was given any.

Question 9

Do the cell therapies that restore C-peptide bring measurable benefits?

Accepted Answer

Yes, in small early trials, and C-peptide is how the benefit is detected rather than where it comes from. In the 2025 zimislecel trial, all 12 participants in the later parts were free of severe hypoglycemic events and had a glycated hemoglobin level of less than 7%. Ten of those 12, or 83%, had insulin independence and were not using injected insulin at day 365. A 2022 trial of mesenchymal stem cells, a kind of support cell taken from bone marrow, reported that early transplantation significantly improved HbA1c and C-peptide levels in its 21 type 1 patients. Yet a 2024 meta-analysis of 13 such studies found the fasting C-peptide difference was not significant, with a P-value of 0.231. One trial and the pooled studies disagree about C-peptide, which is itself the useful fact.

Question 10

How long did benefits take to appear, and did they last?

Accepted Answer

The infusion studies were short-term, so their effects appeared within that window and nothing is known about duration. The therapies that protect the body's own supply give a clearer picture. In the 2021 anti-interleukin-21 trial of 308 adults, the smaller decline in C-peptide was measured at week 54, and the effects diminished upon treatment cessation. Islet transplant registry data reviewed in 2015 found approximately 50% of the patients who undergo islet transplantation are insulin independent after a 3-year follow-up. So the pattern across these sources is that a benefit holds while the therapy or the graft keeps working, and fades when it stops. That is a fact about those therapies, and it does not carry to C-peptide given by drip.

Question 11

Does a benefit in type 1 diabetes carry to type 2?

Accepted Answer

Not automatically, because the starting point differs. Type 1 means little or no C-peptide, while type 2 usually means plenty of it alongside insulin resistance. The 2004 review reports that the pump defect seen in type 1 is less impaired or even normal in type 2 diabetic patients. Transplant outcomes differ too, and a 2019 study of 112 pancreas transplants found patients with type 2 disease are more likely to have posttransplant pancreatitis and BK virus nephropathy, a viral kidney infection, affecting the net benefit for transplant. The same study still concluded pancreas transplant can be performed with excellent and equivalent outcomes in type 1 and carefully selected type 2 diabetes. Carefully selected is the qualifier that matters. A benefit shown in one group belongs to that group until it is measured in the next.

Question 12

Which hoped-for benefits have never been measured?

Accepted Answer

Anything outside diabetes. None of the research behind this page measures C-peptide's effect on weight, energy, muscle, skin or ageing, and none gives it to a person without diabetes. Even inside diabetes, the 2023 review says the complex pattern of the link between C-peptide and chronic complications has not yet been fully understood. The 1982 review in Diabetes Care placed its main value elsewhere, in clinical research, where it offers a unique opportunity to follow the B-cell secretion in diabetic subjects. A claimed benefit outside diabetes would be a claim about a question these studies did not ask. That is not evidence against such a benefit; it is the absence of any evidence for it, and those are different things.

Question 13

What would it take to show a benefit in a healthy adult?

Accepted Answer

A randomised trial in people whose own C-peptide is normal, with a placebo arm, a stated amount, and an outcome that matters to them, run long enough to see it. Even for diabetes, the 2017 kidney review wrote that clinical trials of C-peptide in diabetic nephropathy are both justified and urgently required. If the case for trials was still being made for the group with the strongest reason to try it, the case for healthy adults has not been opened. There is also a reason to expect less in a healthy body. Every mechanism described on this page is about restoring something missing, and a body already making normal amounts has nothing to restore. What is documented about harm, and why that record is so thin, is covered on the C-peptide safety page.

C-peptide: what the research measured